Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MVA-mBN32 in HIV-1 Infected Patients
NCT00390078Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Jan 2007
- Primary completion
- Dec 2007
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MVA-mBN32 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bavarian Nordic. Primary endpoint: Safety and reactogenicity of recombinant MVA-mBN32 and MVA-BN at 24 weeks. Started Jan 2007; status: completed.
02
Drugs
MVA-mBN32
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00390078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390078.